Dr. Waggoner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9500 Euclid Avenue/A81
Cleveland, OH 44195Phone+1 216-445-3410Fax+1 216-444-8551- Is this information wrong?
Summary
- I am a Board Certified Gynecologic Oncologist specializing in the treatment of women with cancer or suspected cancer of the female reproductive system.
I am a surgeon and chemotherapy specialist (including HIPEC and immunotherapy) for women with cancer of the ovaries, tubes, uterus, cervix, vulva and vagina.
I assist women with genetic predisposition to gynecologic cancers on means of reducing this risk.
NIH funded clinical research through the NCTN has been a focus of my career for 30+ years. I currently serve as the contact Principal Investigator for NRG Oncology at Case Western Reserve University and its affiliates.
Additional professional interests of mine include cancer survivorship for women and caregivers, patient safety, and management of treatment related side effects.
Educating and mentoring students, residents, fellows and nurses in the specialty of Gynecologic Oncology is a vital part of my career.
Education & Training
- Georgetown University HospitalFellowship, Gynecologic Oncology, 1988 - 1991
- University of ChicagoResidency, Obstetrics and Gynecology, 1984 - 1988
- University of Washington School of MedicineClass of 1984
Certifications & Licensure
- OH State Medical License 2002 - 2025
- IL State Medical License 1984 - 2008
- MD State Medical License 1988 - 1991
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- “America’s Top Doctors” Citation (Castle Connolly) 2001-2023
- University Hospitals Cleveland Medical Center Distinguished Physician Award 2019
- Anderson Family Endowed Master Clinician in Gynecologic Oncology University Hospitals of Cleveland, 2015
Clinical Trials
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Join now to see all
Publications & Presentations
PubMed
- Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.Lilian T Gien, Danielle M Enserro, Linda R Duska, Andrea E Wahner-Hendrickson, Premal H Thaker, Allan Covens, Kathleen N Moore, Robert L Coleman, Matthew S Block, Stev...> ;Gynecologic Oncology. 2024 Apr 10
- 1 citationsSafety and efficacy of topical artesunate for the treatment of vulvar intraepithelial neoplasia 2/3.Chad M Michener, Stephanie Ricci, Mariam AlHilli, Lindsey Beffa, Robert Debernardo, Steven E Waggoner, Jennifer Brainard, Mihaela Plesa, Jerome L Belinson, Cornelia L ...> ;Gynecologic Oncology. 2023 Nov 1
- 2 citationsMixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic...Ian S Hagemann, Wei Deng, Richard J Zaino, Matthew A Powell, Camille Gunderson Jackson, Casey Cosgrove, Cara Mathews, Michael L Pearl, Steven Waggoner, Rahel Ghebre, S...> ;Gynecologic Oncology. 2023 Oct 1
- Join now to see all
Press Mentions
- NRG Oncology Announces Leadership of New Diversity, Equity, and Inclusion Committee, New Vice Chair for Ancillary Projects CommitteeDecember 12th, 2022
- Clinical Trial Underscores Promise of Immunotherapy, in Combination with Second Drug, for Ovarian CancerJuly 13th, 2019
- Case Comprehensive Cancer Center Awarded $8.9 Million to Expand Access to Clinical TrialsMay 16th, 2019
- Join now to see all
Grant Support
- 12. Co-Investigator: CWRU NCTN Lead Academic Participating Site.NIH2013–2024
- Chair, Gynecologic Oncology Group Ancillary Data Subcommittee.NIH2004–2013
- Principal Investigator: Clinical Trials in Gynecologic OncologyNIH1992–2013
Committees
- Chair, NRG Oncology Ancillary Project Comittee 2022 - Present
- Member, NRG Oncology Membership Committee 2013 - Present
- Vice Chair, NRG Oncology Ancillary Project Committee 2014 - 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: